基因工程腺病毒治疗裸鼠骨肉瘤肺转移的实验研究  

Effect of genetically modified adenovirus H101 on nude mice model of osteosarcoma with lung metastasis

作　　者：徐立辉[1] 蔡槱伯[1] 王迪凡[1] 

机构地区：[1]北京大学第四临床医学院(北京积水潭医院)骨肿瘤科,北京100035

出　　处：《中华肿瘤防治杂志》2009年第14期1066-1068,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:研究基因工程腺病毒对骨肉瘤裸鼠模型局部原发肿瘤和远处转移灶的作用。方法:裸鼠皮下注射人骨肉瘤细胞株OS-732,建立骨肉瘤裸鼠模型,随机分为处理组(15只)和对照组(14只)。处理组以基因工程腺病毒(H101)瘤内注射,对照组以DMEM液注射。观察局部肿瘤和远处转移灶的肿瘤平均直径和质量,以及肺转移结节数和肺转移总结节数,以流式细胞仪分析处理组和对照组局部肿瘤的异倍体含量。结果:处理组和对照组局部肿瘤及远处转移灶的肿瘤平均直径、质量和异倍体含量差异无统计学意义,P>0.05。处理组和对照组的肺转移结节数分别为4.20±2.33和3.57±2.20,差异无统计学意义,t=0.745,P=0.463;两组肺转移总结节数分别为11.00±6.43和9.57±6.17,差异也无统计学意义,t=0.611,P=0.547。结论:H101不能明显抑制裸鼠骨肉瘤的局部肿瘤生长和远处转移。OBJECTIVE：To investigate the effect of genetically modified adenovirus H101 on nude mice model of human osteosarcoma. METHODS; Incubate OS-732 cell line on 29 nude mice were divided into treatment group and control group, The genetically modi lied adenovirus H101 was injected into the primary tumor in the treatment group and DMEM was injected intratumorally in the control group. Observe the mean diameter and the wet weight of the primary tumor and the distant metastasis. Calculate the lung metastasis nodules and the total metastasis nodules. They were also analyzed by FCM. RESULTS： There were no significant differences with the mean diameter,wet weight and the aneuploid percents of the primary tumors and the distant metastasis tumors between the treatment group and the control group （P〉0. 05）. The lung metastasis nodules of the treatment group and the control group were 4.20±2.33 and 3.57±2.20, respectively. There were no significant differences（t=0. 745, P=0. 463） ; The total lung metastasis nodules of the treatment group and the control group are 11.00±6.43 and 9.57±6.17, respectively. There are no significant differences （t=0. 611, P=0. 547）. CONCLUSION： The genetically modified adenovirus H101 can not inhibit the growth and metastasis tendency of the osteosarcoma in this nude mice model.

关 键 词：骨肉瘤/病理学 基因表达 肺肿瘤/继发性 小鼠 裸 

分 类 号：R738[医药卫生—肿瘤] R734.2[医药卫生—临床医学]